Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Age
Meaghan C Creed, Norton W Milgram

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia, affecting an estimated 4.8 million people in North America. For the past decade, the amyloid cascade hypothesis has dominated the field of AD research. This theory posits that the deposition of amyloid-beta protein (Abeta) in the brain is the key pathologic event in AD, which induces a series of neuropathological changes that manifest as cognitive decline and eventual dementia. Based on this theory, interventions that reduce Abeta burden in the brain would be expected to alleviate both the neuropathological changes and dementia, which characterize AD. Several diverse pharmacological strategies have been developed to accomplish this. These include inhibiting the formation of Abeta, preventing the aggregation of Abeta into insoluble aggregates, preventing the entry of Abeta into the brain from the periphery and enhancing the clearance of Abeta from the central nervous system. To date, no amyloid-modifying therapy has yet been successful in phase 3 clinical trials; however, several trials are currently underway. This article provides a review of the status of amyloid-modifying therapies and the implications for the amyloid cascade hypothesis.

References

Oct 1, 1991·Trends in Pharmacological Sciences·J Hardy, D Allsop
Sep 1, 1988·Neurobiology of Aging·L C WalkerL C Cork
Nov 21, 1986·Neuroscience Letters·M YokoyamaD W Choi
Jan 1, 1993·Neuron·J H WeissD W Choi
Apr 20, 1994·Biochemical Pharmacology·R M Nitsch, J H Growdon
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R M NitschR J Wurtman
Aug 2, 1996·The Journal of Biological Chemistry·D J Selkoe
Feb 14, 1998·Neurobiology of Aging·C S von KochS S Sisodia
May 26, 1998·Journal of Molecular Biology·J McLaurinP E Fraser
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y LiuD Schubert
Apr 7, 1999·Neurobiology of Aging·B A in 't VeldB H Stricker
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·F MagaraD P Wolfer
Sep 11, 1999·Trends in Neurosciences·W Annaert, B De Strooper
Jul 13, 2000·Archives of Neurology·D B SchenkJ Wallace
Nov 23, 2000·Journal of Neuropathology and Experimental Neurology·A NunomuraM A Smith
Jan 9, 2001·Journal of Neurochemistry·H F DoveyJ E Audia
Feb 13, 2001·Neurobiology of Aging·J JosephM A Smith
Feb 22, 2001·Free Radical Biology & Medicine·C A RottkampM A Smith
Apr 11, 2001·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·N PapaioannouE Gruys
Apr 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·K FassbenderT Hartmann

❮ Previous
Next ❯

Citations

Jan 19, 2011·Journal of Cardiovascular Pharmacology·Jing XiongMuthuvel Jayachandran
Apr 2, 2013·Journal of Leukocyte Biology·Katrin Kierdorf, Günter Fritz
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jaren W LandenMartin M Bednar
Oct 25, 2011·Journal of Neuroscience Methods·Harry D SamarooDiane T Stephenson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.